Biologically defined neuronal synuclein disease as a tool to advance drug development.
Saved in:
| Title: | Biologically defined neuronal synuclein disease as a tool to advance drug development. |
|---|---|
| Authors: | Pagano G; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. gennaro.pagano@roche.com.; University of Exeter Medical School, London, UK. gennaro.pagano@roche.com., Dam T; Neumora Therapeutics, Watertown, MA, USA., Kerchner GA; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Galpern WR; Janssen Research & Development, LLC, Cambridge, MA, USA., Biagioni M; UCB Pharma, Brussels, Belgium., Karan R; Global Drug Development, Novartis Pharma AG, Basel, Switzerland., Jennings D; Denali Therapeutics Inc., South San Francisco, CA, USA., Peterschmitt MJ; Sanofi, Clinical Development Neurology, Cambridge, MA, USA., Nikolcheva T; Product Development Neurology, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Brundin P; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. |
| Source: | NPJ Parkinson's disease [NPJ Parkinsons Dis] 2024 Dec 20; Vol. 10 (1), pp. 235. Date of Electronic Publication: 2024 Dec 20. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 101675390 Publication Model: Electronic Cited Medium: Print ISSN: 2373-8057 (Print) Linking ISSN: 23738057 NLM ISO Abbreviation: NPJ Parkinsons Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2373-8057 |
|---|---|
| DOI: | 10.1038/s41531-024-00845-5 |
